title: Presumed masitinib-induced nephrotic syndrome and azotemia in a dog.
abstract: Masitinib mesylate is a tyrosine-kinase inhibitor approved for the treatment of nonresectable or recurrent, Grade 2 or 3 mast cell tumors in dogs. This report describes nephrotic syndrome and acute kidney injury attributed to masitinib and illustrates the need for regular monitoring of serum creatinine concentration, urinalysis, and urine protein:creatinine ratio during its use.
authors.affiliation: North Carolina State Veterinary Hospital - Internal Medicine, 1060 William Moore Drive, Raleigh, North Carolina 27607, USA (Devine); University of Minnesota - Internal Medicine, St. Paul, Minnesota, 55108, USA (Polzin).
authors.forename: Lauren
authors.initials: L
authors.lastname: Devine
authors.affiliation: North Carolina State Veterinary Hospital - Internal Medicine, 1060 William Moore Drive, Raleigh, North Carolina 27607, USA (Devine); University of Minnesota - Internal Medicine, St. Paul, Minnesota, 55108, USA (Polzin).
authors.forename: David J
authors.initials: DJ
authors.lastname: Polzin
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D053099:Azotemia / Q000139:chemically induced / Q000662:veterinary*; D001549:Benzamides; D004283:Dog Diseases / Q000139:chemically induced*; D004285:Dogs; D005260:Female; D034801:Mastocytoma / Q000188:drug therapy / Q000662:veterinary; D009404:Nephrotic Syndrome / Q000139:chemically induced / Q000662:veterinary*; D010880:Piperidines; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011725:Pyridines; D013844:Thiazoles / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010880:Piperidines; D011725:Pyridines; D013844:Thiazoles; D011505:Protein-Tyrosine Kinases; C526575:masitinib